期刊文献+

半乳凝集素-3对心力衰竭患者的诊断及评估作用 被引量:2

Diagnosis and evaluation of Galectin - 3 in patients with heart failure
下载PDF
导出
摘要 目的探讨半乳凝集素-3(Galectin-3,Ga-3)对心力衰竭(心衰)患者的诊断及评估作用。方法选取40例心力衰竭患者,测定治疗前后Ga-3、脑钠肽(BNP),行Ga-3与BNP的相关性分析,行Ga-3与心功能分级的相关性分析。治疗1周后检查心脏彩超,测定射血分数(EF)、左室舒张末期内径(LVEDD),行Ga-3、BNP与EF、LVEDD的相关性分析,按治疗效果分为有效组及无效组,比较两组治疗前后Ga-3、BNP水平。按心功能分级分组,比较各组Ga-3、BNP水平。随访3个月,记录再住院及死亡事件。结果①Ga-3与BNP、LVEDD、心功能分级呈正相关,Ga-3、BNP与EF呈负相关。②治疗有效组治疗后BNP较治疗前明显下降(P〈0.05),而Ga-3未见明显下降(P〉0.05)。治疗无效组治疗后Ga-3、BNP较治疗前明显升高(P〈0.05)。③随访3个月,发生心脏不良事件组Ga-3、BNP水平较不发生心脏不良事件组明显升高。结论Ga-3与心衰患者心肌重构有关,可评估心衰患者预后,可作为诊断治疗、危险分层及评估预后的生物标志物。 Objective To investigate the diagnosis and evaluation of Galectin -3 in patients with heart failure. Methods Forty patients with heart failure were included in this study. Before and after treatment, Galectin -3, BNP were measured. The relationship between Ga -3 and BNP was analyzed. One week after treatment, echocardiography was performed and EF, LVEDD were measured. The relationship between Ga - 3, BNP and EF, LVEDD was analyzed. The treatment effect was divided into effective group and ineffective group. The levels of Ga - 3, BNP of the two groups were compared. Grouping according to cardiac function, correlation between Ga - 3 and cardiac function classification was analyzed. The patients were followed up for 3 months to record the information about rehospitalization and death. Results ①Correlation analysis showed that the serum levels of Ga -3 and BNP, LVEDD, cardiac functional grading had a positive correlation; Correlation analysis showed that the serum levels of Ga-3, BNP and EF had a negative correlation. ②The effective rate of BNP in treatment group was significantly lower than that before treatment ( P 〈 0.05 ) ; No significant decrease was seen in Ga - 3 ( P 〉 0.05). After treatment, the Ga -3 and BNP of the treated group were significantly higher than those before treatment (P 〈 0.05). ③The patients were followed up for 3 months, the level of Ga - 3, BNP in the adverse event group was significantly higher than that in the group without adverse cardiac events. Conclusion In patients with heart failure, correlation analysis shows that the serum levels of Ga - 3 and cardiac hypofunction, myocardial remodeling have a negative correlation. It can assess the prognosis in patients with heart failure. It can be used as a new biomarker for diagnosis, treatment, risk stratification and evaluation of prognosis in patients with heart failure.
出处 《中国急救医学》 CAS CSCD 北大核心 2018年第1期37-40,共4页 Chinese Journal of Critical Care Medicine
关键词 心力衰竭 半乳凝集素-3 心肌重构 预后 Heart failure Galectin - 3 Myocardial remodeling Prognosis
  • 相关文献

参考文献3

二级参考文献36

  • 1Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused up- date incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Re- port of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guide- lines Developed in Collaboration With the International Soci- ety for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-e90.
  • 2Nakahara S, Oka N, Wang Y, et al. Characterization of the nuclear import pathways of Galectin-3. Cancer Res 2006; 66: 9995-10006.
  • 3van Kimmenade RR, Januzzi JL Jr., Ellinor PT, et al. Utilityof amino-terminal pro-brain natriuretic peptide, Galectin-3, and apelin for the evaluation of patients with acute heart fail- ure. JAm Coll Cardio12006; 48: 1217-1224.
  • 4Lok D J, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin ResCardio12010; 99: 323-328.
  • 5Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008; 58:88-111.
  • 6Ueland T, Aukmst P, Broch K, et al. Galectin-3 in heart fail- ure: high levels are associated with all cause mortality, lnt J Cardio12011; 150:361 364.
  • 7van der Velde AR, Gullestad L, Ueland T, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure data from CORONA and COACH. Circ" Heart Fail 2013; 6: 219326.
  • 8Milting H, Ellinghaus P, Seewald M, et al. Plasma biomarkers of mycordial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008; 27:589 596.
  • 9Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2012; 58: 267-273.
  • 10de Boer RA, Verweij N, van Veldhuisen D J, et al. A ge- home-wide association study of circulating galectin-3. PLoS ONE 2012; 7: e47385.

共引文献41

同被引文献23

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部